Cefaclor: adverse event reports filed with FDA

729

reports as suspect product

0% of all reports · about 33 a year

38

reports, 12 months to June 2026

39 in the 12 months before

78.9%

marked serious by the reporter

89.1% across the class

4.8%

record death among outcomes, as reported

35 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Cefaclor reports recording the termmedian drug in cephalosporin antibacterial

1. Drug hypersensitivityan allergic-type reaction to a medicine33.5%244
2. Vomitingbeing sick15.9%116
3. Nauseafeeling sick15%109
4. Fatiguetiredness12.8%93
5. Drug intolerancethe medicine was not tolerated12.6%92
6. Infectionan infection, type not specified12.2%89
7. International normalised ratio fluctuation12.1%88
8. Therapeutic product effect incomplete11.5%84
9. Bloody discharge9.3%68
10. Drug ineffectivethe medicine did not work as expected9.3%68
11. Dizzinesslight-headedness or unsteadiness9.2%67
12. Lyme disease9.2%67
13. Urticariahives7.7%56
14. Diarrhoealoose or frequent stools7.4%54
15. Abdominal painstomach or belly pain7.1%52
16. Dyspnoeashortness of breath7%51
17. Rashskin rash7%51
18. Hypersensitivityan allergic-type reaction6.7%49
19. Malaisegeneral feeling of being unwell6.6%48
20. Pruritusitching6.4%47
21. Staphylococcal infection6%44
22. Hypoaesthesianumbness5.6%41
23. Iron deficiency5.6%41
24. Platelet count increased5.6%41
25. Rash erythematousa red rash5.5%40
26. Pain in extremitypain in an arm or leg5.3%39
27. Red blood cell sedimentation rate increased5.2%38
28. Secretion discharge5.2%38
29. Clostridium difficile infection4.8%35
30. Angioedemadeep swelling of skin or mucous membranes4.7%34

Top 30 of 321 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the cephalosporin antibacterial class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 57,006 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 25.2% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 729 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the cephalosporin antibacterial class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Cefaclor as a suspect or interacting product; reports listing it only as a concomitant medication (829) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.